Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CKS1B | P61024 | 1/20 | 0.56 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367383 | 0.87 | NR3C1 (0.65) | NR3C1PGRNR3C2ARLMNA | |
| SCHEMBL1984869 | 0.86 | CA1 (0.60) | NR3C1PGRNR3C2ARKMT2A | |
| SCHEMBL2367735 | 0.86 | NR3C1 (0.60) | NR3C1PGRNR3C2ARLMNA | |
| SCHEMBL2403697 | 0.85 | TUBB4A (0.61) | NR3C1PGRNR3C2ARLMNA | |
| SCHEMBL3061022 | 0.82 | GLO1 (0.58) | NR3C1PGRNR3C2ARSLC40A1 | |
| SCHEMBL3073814 | 0.82 | NR3C1 (0.56) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3061760 | 0.82 | NR3C1 (0.56) | NR3C1PGRNR3C2ARKMT2A | |
| SCHEMBL2367583 | 0.82 | NFKBIA (0.58) | NR3C1PGRNR3C2ARLMNA | |
| SCHEMBL3071489 | 0.82 | NR3C1 (0.56) | NR3C1PGRNR3C2ARLMNA | |
| SCHEMBL3055215 | 0.82 | NR3C1 (0.56) | NR3C1PGRNR3C2ARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366687-B1 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO LTD (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-8173693-B2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2012-05-08 | — | — | US | disclosed |
| US-8173693-B2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2012-05-08 | — | — | US | disclosed |
| CN-102199148-A | Benzenesulfonamide derivatives and pharmaceutical compositions thereof | PURZER PHARMACEUTICAL CO LTD | 2011-09-28 | — | — | CN | disclosed |
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2011-09-22 | — | — | US | disclosed |
| EP-2366687-A2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | Purzer Pharmaceutical Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | CCNI, CCNE1, CCND1 | NR3C1 4137/4885PGR 1644/4885NR3C2 4025/4885 |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | NR3C1 1/4885PGR 325/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.